1Steward PM,Janes RA.The future of somatostatin analogue therapy.Baillieres Best Pract Res Clin Endocrinol Metab,1999,13:409-418.
2Froidevaux S,Eberle AN.Somatostatin analogs and radiopeptides in cancer therapy.Biopolymers,2002,66:161-183,
3Pinzani P,Orlando C,Ragi CC,et al.Type-2 somatostatin receptor mRNA levels in breast and colon cancer determined by a quantitative RT-PCR assay based on dual label fluorogenic probe and the TaqMan technology.Regul Pept,2001,99:79-86.
4Reubi JC,Zimmermann A,Jonas S,et al.Regulatory peptide receptors in human hepatocellular carcinomas.Gut,1999,45:766-774.
5Denzler B,Reubi JC,Expression of somatostatin receptors in peritumoral veins of human tumors.Cancer,1999,85:188-198.
6Bernhardt P,Benjegard SA,Kolby L,et al.Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors.Int J Radiat Oncol Biol Phys,2001,51:514-524.
7A.Heppeler,S.Froidevaux,H.R.Macke,et al,Radiometal-labelled macrocyclic chelator derivatised somatostation analogue with superb tumor targeting properties and potential for receptor mediated internal radiotherapy,Chem Eur J,1999,5,1974-1981.
8Krenning EP,Valkema R,Kooij PP,et al.The role of radioactive somatostatin and its analogues in the control of tumor growth.Recent Results Cancer Res,2000,153:1-13.
9Weigel P.Mechanisms of cellular processing and degradation of internalized soluble glycoproteins.In:Allen HJ,Kisaulis EC,eds.Glycoconjugates,composition,structure and function.New York:Marcel Dekker,Inc,1992.
